US2010267079A1PendingUtilityA1

Identification and isolation of transitional cell carcinoma stem cells

Assignee: WEISSMAN IRVING LPriority: Dec 7, 2006Filed: Jun 16, 2010Published: Oct 21, 2010
Est. expiryDec 7, 2026(~0.4 yrs left)· nominal 20-yr term from priority
G01N 33/57505C12N 5/0695G01N 2333/70585
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Transitional cell carcinoma stem cells (TCCSC) are identified. The cells can be prospectively isolated or identified from primary tumor samples, and are shown to possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation, and in cancer diagnosis.

Claims

exact text as granted — not AI-modified
1 - 10 . (canceled) 
     
     
         11 . A composition of mammalian transitional cell carcinoma stem cells, wherein at least 50% of the cells in said composition are CD44 +  CK5 +  transitional cell carcinoma stem cells (TCCSC). 
     
     
         12 . (canceled) 
     
     
         13 . The composition according to  claim 11 , wherein the TCCSC have increased nuclear localization of β-catenin; Stat3; or Bmi-1. 
     
     
         14 . (canceled) 
     
     
         15 . A method of screening a candidate chemotherapeutic agent for effectiveness against an TCCSC, the method comprising:
 contacting said agent with the cell composition of  claim 11 , and   determining the effectiveness of said agent against said TCCSC.   
     
     
         16 . The method of  claim 15 , further comprising classifying the TCCSC according to increased nuclear localization of β-catenin; Stat3; or Bmi-1 prior to said contacting.

Join the waitlist — get patent alerts

Track US2010267079A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.